Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

It is over 50 years since the discovery of microtubules, and they have become one of the
most important drug targets for anti-cancer therapies. Microtubules are predominantly …

Microtubules (MTs), highly dynamic structures composed of α-and β-tubulin heterodimers,
are involved in cell movement and intracellular traffic and are essential for cell division …

Class III β-tubulin (βIII-tubulin) is frequently overexpressed in human tumors and is
associated with resistance to microtubule-targeting agents, tumor aggressiveness, and poor …

ABI-231 is a potent, orally bioavailable tubulin inhibitor that interacts with the colchicine
binding site and is currently undergoing clinical trials for prostate cancer. Guided by the …

Prostate cancer (PCa) cells exploit the aberrant lipid signaling and metabolism as their
survival advantage. Also, intracellular storage lipids act as fuel for the PCa proliferation …

Purpose: Sabizabulin, an oral cytoskeleton disruptor, was tested in a phase Ib/II clinical
study in men with metastatic castration-resistant prostate cancer (mCRPC). Patients and …

Esophageal cancer (EC) is one of the most incident and lethal tumors worldwide. Although
surgical resection is an important approach in EC treatment, late diagnosis, metastasis and …

Due to the three domains of the colchicine-site which is conducive to the combination with
small molecule compounds, colchicine-site on the tubulin has become a common target for …

Cellular senescence is one of the prevailing issues in cancer therapeutics that promotes
cancer relapse, chemoresistance, and recurrence. Patients undergoing persistent …